Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata.

ABSTRACT:

Introduction

The ALLEGRO- 2b/3 (Clinicaltrials.gov Identifier: NCT03732807) study demonstrated efficacy and safety of ritlecitinib in patients with alopecia areata (AA). Despite clinically meaningful improvement in hair regrowth, differences in patient-reported emotional symptoms or activity limitations (subscales of the Alopecia Areata Patient Priority Outcomes [AAPPO]) between treatment groups were not significant. This study aimed to identify potential factors that may impact the measurement of patient-reported outcomes in AA.

Methods

This mixed methods study conducted remote interviews with individuals with self-reported AA. Interviews were designed to understand how experiences with AA impacted study participant health-related quality of life and gain insights into how

SUBMITTER: Mostaghimi A 

PROVIDER: S-EPMC12092900 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature